HER2-positive carcinoma of breast – Talk Bio

Actionable Insights Powered by AI

Pfizer’s Tukysa Shows Strong PFS Benefit in First-Line HER2+ Breast Cancer Maintenance at SABCS 2025, Sparking Debate with Enhertu

1 month ago talkbio0Tagged Enhertu, first-line maintenance, HER2-positive carcinoma of breast, HER2CLIMB-05, Pfizer, Progression-Free Survival, SABCS, Tukysa

Tukysa; Pfizer; HER2-positive breast cancer; SABCS 2025; HER2CLIMB-05; progression-free survival; Enhertu; first-line maintenance

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

5 months ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, DualityBio, HER2-positive carcinoma of breast, Market, Oncology Pipeline, pamirtecan, Phase 3 trial, Progression-Free Survival, trastuzumab

BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market